Welcome to our dedicated page for Galectin Therapeutics news (Ticker: GALT), a resource for investors and traders seeking the latest updates and insights on Galectin Therapeutics stock.
Galectin Therapeutics Inc. develops therapeutics that target galectin proteins, with its lead program focused on belapectin, a carbohydrate-based galectin-3 inhibitor for MASH cirrhosis and portal hypertension. Company updates commonly cover NAVIGATE clinical-trial results, biomarker analyses, medical-conference presentations, journal publications, and FDA communications related to the belapectin development program.
News also includes financial results, research and development spending, cash-resource updates, credit financing, board composition, and investor or key-opinion-leader events. Galectin has also described additional development interests in combination immunotherapy for advanced head and neck cancers and other malignancies.
Galectin Therapeutics has initiated patient enrollment for the NASH-RX trial, focusing on belapectin as a treatment for nonalcoholic steatohepatitis (NASH) cirrhosis. This adaptively-designed Phase 2b/3 trial targets patients at risk of developing esophageal varices, with a total enrollment of approximately 315 participants across 130 sites in 12 countries. Success in this trial could lead to accelerated FDA approval and partnership opportunities, addressing a significant unmet medical need in the treatment of NASH.
Galectin Therapeutics Inc. (NASDAQ: GALT) reported its Q1 2020 financial results, showing a net loss of $3.6 million ($0.06 per share), an improvement from $9.1 million ($0.20 per share) in Q1 2019. The company has filed a new protocol for its NASH-RX clinical trial with the FDA, aiming to begin patient enrollment in Q2 2020. The trial intends to assess the efficacy of belapectin for treating NASH cirrhosis. Additionally, a $100 million shelf registration statement has been filed with the SEC to facilitate future financing needs as ongoing costs for the clinical program are estimated at $125 million.
Summary not available.